Üriner Sistem Taş Hastalığında Metaflaksi

Kachkoul R, Touimi GB, El Mouhri G, El Habbani R, Mohim M, Lahrichi A. Urolithiasis: history, epidemiology, aetiologic factors and management. Malays J Pathol. 2023;45(3):333-352.

Ferraro PM, Curhan GC, D'Addessi A, Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of the literature. J Nephrol. 2017;30(2):227-233. doi:10.1007/s40620-016-0329-3.

Menditto VG, Milanese G, Muzzonigro G. Metaphylaxis of urolithiasis. Arch Ital Urol Androl. 2009;81(1):32-39.

Türk C, Neisius A, Petrik A, Seitz C, Skolarikos A, Somani B, et al. EAU Guidelines on Urolithiasis. In: EAU Guidelines. 2024 ed. Arnhem (NL): EAU Guidelines Office; 2024.

Lombardo R, Tzelves L, Geraghty R, Davis NF, Neisius A, Petrik A, et al. Follow-up of urolithiasis patients after treatment: an algorithm from the EAU Urolithiasis Panel. World J Urol. 2024;42(1):202.

Norman RW, Bath SS, Robertson WG, Peacock M. When should patients with symptomatic urinary stone disease be evaluated metabolically? J Urol. 1984;132(6):1137-1139.

Goldfarb DS, Arowojolu O. Metabolic evaluation of first-time and recurrent stone formers. Urol Clin North Am. 2013;40(1):13-20.

Domingos F, Serra A. Metabolic syndrome: a multifaceted risk factor for kidney stones. Scand J Urol. 2014;48(5):414-419. doi:10.3109/21681805.2014.903513.

Strohmaier WL, Wrobel BM, Schubert G. Overweight, insulin resistance and blood pressure (metabolic syndrome parameters) in uric acid urolithiasis. Urol Res. 2012;40:171-175. doi:10.1007/s00240-011-0403-9.

Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155(3):839-843.

Shuster J, Finlayson B, Scheaffer RL, et al. Primary liquid intake and urinary stone disease. J Chronic Dis. 1985;38:907-914.

Shuster J, Jenkins A, Logan C, et al. Soft drink consumption and urinary stone recurrence: a randomized prevention trial. J Clin Epidemiol. 1992;45:911-916.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Beverage use and risk for kidney stones in women. Ann Intern Med. 1998;128:534-540.

Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med. 1997;126(7):497-504.

Harris SS, Dawson-Hughes B. Effects of hydration and calcium supplementation on urine calcium concentration in healthy postmenopausal women. J Am Coll Nutr. 2015;34(4):340-346.

Arivoli K, Valicevic AN, Oerline MK, Hsi RS, Patel SR, Hollingsworth JM, et al. Preventive pharmacological therapy and risk of recurrent urinary stone disease. Clin J Am Soc Nephrol. 2024;19(5):565-572.

Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Am J Med. 1980;69(1):19-30.

Coe FL. Treated and untreated recurrent calcium nephrolithiasis. Ann Intern Med. 1977;87(4):404-410.

Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005;115(10):2598-2608.

Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-324.

Pasilan RM, Pawar N, Alawieh R, Hiremath S, Teakell J. Hydrochlorothiazide and prevention of kidney stone recurrence: a #NephJC editorial on the NOSTONE trial. Kidney Med. 2023;5(12):100739. doi:10.1016/j.xkme.2023.100739. PMID:37954501; PMCID:PMC10632949.

Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005;115(6):1651-1658.

Pottegård A, Pedersen SA, Schmidt SAJ, et al. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med. 2018;178(8):1120-1122.

Mandel NS, Mandel GS. Urinary tract stone disease in the United States veteran population. J Urol. 1989;142(6):1516-1521.

Sfoungaristos S, Gofrit ON, Yutkin V, Pode D, Duvdevani M. Prevention of kidney stone recurrence. Expert Opin Pharmacother. 2015;16(8):1209-1218.

Pak CY. Citrate and renal calculi: an update. Miner Electrolyte Metab. 1994;20(6):371-377.

Griffith DP, Musher DM, Itin C. Urease. The primary cause of infection-induced urinary stones. Invest Urol. 1976;13(5):346-350.

Gettman MT, Segura JW. Struvite stones: diagnosis and current treatment concepts. J Endourol. 1999;13(9):653-658.

Wong HY, Griffith DP. Medical management and prevention of struvite stones. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, editors. Kidney Stones: Medical and Surgical Management. Philadelphia: Lippincott-Raven; 1996.

Jarrar K, Boedeker RH, Weidner W. Struvite stones: long-term follow-up under metaphylaxis. Ann Urol (Paris). 1996;30(3):112-117.

Wall I, Tiselius HG. Long-term acidification of urine in patients treated for infected renal stones. Urol Int. 1990;45(6):336-341.

Ng CS, Streem SB. Contemporary management of cystinuria. J Endourol. 1999;13(9):647-651.

Rogers A, Kalakish S, Desai RA, Assimos DG. Management of cystinuria. Urol Clin North Am. 2007;34(3):347-362.

Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol. 2005;20(1):19-24.

Kachkoul R, Touimi GB, El Mouhri G, El Habbani R, Mohim M, Lahrichi A. Urolithiasis: history, epidemiology, aetiologic factors and management. Malays J Pathol. 2023;45(3):333-352.

Ferraro PM, Curhan GC, D'Addessi A, Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of the literature. J Nephrol. 2017;30(2):227-233. doi:10.1007/s40620-016-0329-3.

Menditto VG, Milanese G, Muzzonigro G. Metaphylaxis of urolithiasis. Arch Ital Urol Androl. 2009;81(1):32-39.

Türk C, Neisius A, Petrik A, Seitz C, Skolarikos A, Somani B, et al. EAU Guidelines on Urolithiasis. In: EAU Guidelines. 2024 ed. Arnhem (NL): EAU Guidelines Office; 2024.

Lombardo R, Tzelves L, Geraghty R, Davis NF, Neisius A, Petrik A, et al. Follow-up of urolithiasis patients after treatment: an algorithm from the EAU Urolithiasis Panel. World J Urol. 2024;42(1):202.

Norman RW, Bath SS, Robertson WG, Peacock M. When should patients with symptomatic urinary stone disease be evaluated metabolically? J Urol. 1984;132(6):1137-1139.

Goldfarb DS, Arowojolu O. Metabolic evaluation of first-time and recurrent stone formers. Urol Clin North Am. 2013;40(1):13-20.

Domingos F, Serra A. Metabolic syndrome: a multifaceted risk factor for kidney stones. Scand J Urol. 2014;48(5):414-419. doi:10.3109/21681805.2014.903513.

Strohmaier WL, Wrobel BM, Schubert G. Overweight, insulin resistance and blood pressure (metabolic syndrome parameters) in uric acid urolithiasis. Urol Res. 2012;40:171-175. doi:10.1007/s00240-011-0403-9.

Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155(3):839-843.

Shuster J, Finlayson B, Scheaffer RL, et al. Primary liquid intake and urinary stone disease. J Chronic Dis. 1985;38:907-914.

Shuster J, Jenkins A, Logan C, et al. Soft drink consumption and urinary stone recurrence: a randomized prevention trial. J Clin Epidemiol. 1992;45:911-916.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Beverage use and risk for kidney stones in women. Ann Intern Med. 1998;128:534-540.

Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med. 1997;126(7):497-504.

Harris SS, Dawson-Hughes B. Effects of hydration and calcium supplementation on urine calcium concentration in healthy postmenopausal women. J Am Coll Nutr. 2015;34(4):340-346.

Arivoli K, Valicevic AN, Oerline MK, Hsi RS, Patel SR, Hollingsworth JM, et al. Preventive pharmacological therapy and risk of recurrent urinary stone disease. Clin J Am Soc Nephrol. 2024;19(5):565-572.

Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Am J Med. 1980;69(1):19-30.

Coe FL. Treated and untreated recurrent calcium nephrolithiasis. Ann Intern Med. 1977;87(4):404-410.

Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005;115(10):2598-2608.

Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-324.

Pasilan RM, Pawar N, Alawieh R, Hiremath S, Teakell J. Hydrochlorothiazide and prevention of kidney stone recurrence: a #NephJC editorial on the NOSTONE trial. Kidney Med. 2023;5(12):100739. doi:10.1016/j.xkme.2023.100739. PMID:37954501; PMCID:PMC10632949.

Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005;115(6):1651-1658.

Pottegård A, Pedersen SA, Schmidt SAJ, et al. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med. 2018;178(8):1120-1122.

Mandel NS, Mandel GS. Urinary tract stone disease in the United States veteran population. J Urol. 1989;142(6):1516-1521.

Sfoungaristos S, Gofrit ON, Yutkin V, Pode D, Duvdevani M. Prevention of kidney stone recurrence. Expert Opin Pharmacother. 2015;16(8):1209-1218.

Pak CY. Citrate and renal calculi: an update. Miner Electrolyte Metab. 1994;20(6):371-377.

Griffith DP, Musher DM, Itin C. Urease. The primary cause of infection-induced urinary stones. Invest Urol. 1976;13(5):346-350.

Gettman MT, Segura JW. Struvite stones: diagnosis and current treatment concepts. J Endourol. 1999;13(9):653-658.

Wong HY, Griffith DP. Medical management and prevention of struvite stones. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, editors. Kidney Stones: Medical and Surgical Management. Philadelphia: Lippincott-Raven; 1996.

Jarrar K, Boedeker RH, Weidner W. Struvite stones: long-term follow-up under metaphylaxis. Ann Urol (Paris). 1996;30(3):112-117.

Wall I, Tiselius HG. Long-term acidification of urine in patients treated for infected renal stones. Urol Int. 1990;45(6):336-341.

Ng CS, Streem SB. Contemporary management of cystinuria. J Endourol. 1999;13(9):647-651.

Rogers A, Kalakish S, Desai RA, Assimos DG. Management of cystinuria. Urol Clin North Am. 2007;34(3):347-362.

Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol. 2005;20(1):19-24.